• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics Presents Further Data From Its Histone Deacetylase Inhibitor Program As Cancer Therapeutics

SOUTH SAN FRANCISCO, CA - November 16, 2005

Celera Genomics Group (NYSE:CRA), an Applera Corporation business, today announced that its scientists will present three posters describing data from its histone deacetylase (HDAC) inhibitor program at the American Association for Cancer Research (AACR) International Conference on Molecular Targets and Cancer Therapeutics meeting, being held November 14-18, 2005, in Philadelphia, PA.

Two of the posters that are being presented at the AACR meeting describe the inhibition of the HDAC enzyme activity that leads to tubulin and histone acetylation. The first poster, entitled "CRA-024781: A Potent HDAC Inhibitor, with Antitumor Activity in vitro and in vivo," reported extensive molecular profiling of CRA 024781, which is currently undergoing Phase I clinical assessment. CRA-024781 was found to inhibit human tumor cell growth at sub-micromolar concentrations in vitro, and exhibits effects on several mechanistic biomarkers in vitro. Additionally, CRA-024781 was shown to induce the upregulation of specific genes at early time points and down regulation of different genes at later time points in certain tumors which respond to CRA-024781. It may be possible to utilize such gene expression profiles to optimally target CRA-024781 to specific tumors. These preclinical findings further support the application of CRA 024781 as an anti cancer therapy and may be incorporated into Celera's clinical trial strategy for CRA-024781.

The second poster, entitled "CRA-026440, a potent HDAC inhibitor, as an anti-cancer agent," focuses on Celera Genomics' HDAC backup compound CRA-026440 currently in preclinical development. CRA-026440 is a broad spectrum HDAC inhibitor that exhibited growth-inhibitory activities at sub-micromolar concentrations in vitro against a panel of human cancer cell lines. CRA-026440 has significant anti-tumor activity and was well tolerated in an HCT 116 tumor xenograft model. Additive efficacy was observed when CRA-026440 was combined with 5-FU or Avastin® in a colon tumor xenograft study. Furthermore, expression profiling analysis of CRA-026440 in vivo identified a set of genes that may contribute to the understanding and application of CRA-026440 as an HDAC inhibitor in anti-cancer therapy.

The third poster, entitled "The Design of Substituted Phenyl Hydroxamic Acids as Inhibitors of Histone Deacetylases," outlined the design of substituted phenyl hydroxamic acids as HDAC inhibitors. The elucidation of the three-dimensional structure of the HDAC-8 isoform with inhibitors bound at the active site was instrumental in the discovery and design of selective and potent HDAC inhibitors with good pharmaceutical properties. These studies provided additional data following the first report of the crystal structure of the enzyme HDAC-8 published by Celera Genomics in the journal Structure in July 2004.

"We're encouraged with the progress we've continued to make in our HDAC inhibitor program this year," said Robert Booth, Ph.D., Chief Scientific Officer of Celera Genomics. "These findings provide insights into the mechanism of action for these HDAC inhibitors and have generated a wealth of proprietary knowledge towards advancing our program in the most cost effective and timely manner."

About CRA-024781
HDAC inhibitors target HDAC enzymes resulting in inhibition of the proliferation of cancer cells and induction of cancer cell death or apoptosis¹ . Celera Genomics reported in July 2005, the initiation of Phase I clinical testing for its novel HDAC inhibitor, CRA-024781, in patients with refractory solid malignancies. This Phase I trial is a dose-escalation study being conducted at the University of Chicago Hospitals in the Section for Hematology/Oncology. The objectives of the study are to determine the maximum tolerated dose and to evaluate the safety and pharmacokinetics of CRA-024781. Up to 40 patients are being enrolled in this study.

Histone deacetylation is carried out by a family of related HDAC enzymes. Inhibition of these enzymes causes changes to chromatin structure and to gene expression patterns, which result in the inhibition of proliferation of cancer cells and induction of apoptosis. Celera Genomics published the first three-dimensional structure of an HDAC enzyme in July 2004, and this information has been used to aid the design of a series of novel HDAC inhibitors.

About Celera Genomics and Applera Corporation
Applera Corporation consists of two operating groups. The Celera Genomics Group is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at www.celera.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "should," and "planned," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) Celera Genomics' unproven ability to discover, develop, or commercialize proprietary therapeutic products; (2) the risk that clinical trials of products that Celera Genomics do discover and develop will not proceed as anticipated or may not be successful, or that such products will not receive required regulatory clearances or approvals; (3) the uncertainty that Celera Genomics' products will be accepted and adopted by the market, including the risk that that these products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for these products from third party payors such as private insurance companies and government insurance plans; (4) uncertainty of the availability to Celera Genomics of intellectual property protection, limitations on their ability to protect trade secrets, and the risk to them of infringement claims; and (5) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

###

Copyright © 2005. Applera Corporation. All Rights Reserved. Applied Biosystems, Celera, Celera Diagnostics, Celera Discovery System, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.

¹Johnstone, RW. Histone-Deacetylase Inhibitors: Novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 2002, 1:287-299.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.